Compare BETR & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | IMRX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.8M | 288.6M |
| IPO Year | 2021 | 2021 |
| Metric | BETR | IMRX |
|---|---|---|
| Price | $13.55 | $5.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $17.20 |
| AVG Volume (30 Days) | ★ 677.0K | 667.6K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.88 | ★ 37.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,872,000.00 | N/A |
| Revenue This Year | $55.02 | N/A |
| Revenue Next Year | $65.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 51.97 | N/A |
| 52 Week Low | $13.18 | $3.25 |
| 52 Week High | $94.06 | $10.08 |
| Indicator | BETR | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 63.48 |
| Support Level | N/A | $4.82 |
| Resistance Level | $28.72 | $5.27 |
| Average True Range (ATR) | 2.31 | 0.22 |
| MACD | -0.44 | 0.11 |
| Stochastic Oscillator | 1.89 | 92.56 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.